Table 3.
Trials of chemotherapy vs. chemoradiotherapy followed or preceded by chemotherapy in LAPC
| Author;[ref] year | 5-FU plus arms | n | RT dose | Outcome |
|---|---|---|---|---|
| Hazel J;[56] 1981 | 5-FU + methyl-CCNU | 15 | Median OS 7.8 versus 7.3 months | |
| RT + 5-FU Post CRT: 5-FU + methyl-CCNU | 15 | 46 Gy | ||
| Klaassen D;[57] 1985 | 5-FU weekly | 44 | Median OS 8.2 versus 8.3 months | |
| RT + 5-FU Post CRT: 5-FU weekly bolus | 47 | 40 Gy | ||
| GITSG;[58] 1988 | 5-FU + STZ + mitomycin | 21 | Median OS significantly better with CRT (42 versus 32 weeks) | |
| RT + 5-FU. Post CRT: 5-FU + streptozocin + mitomycin | 22 | 54 Gy | ||
| Chauffert B;[59] 2008 | Gemcitabine | 60 | Median OS significantly better with chemotherapy alone (14.3 versus 8.4 mo) | |
| RT + 5-FU + cisplatin days 1–5 every week. Post CRT: Gemcitabine | 59 | 60 Gy | ||
| Loehrer P;[54] 2011 | Gemcitabine | 37 | Median OS significantly better with CRT (11.1 versus 9.2 months) | |
| RT versus Gemcitabine | 34 | 50.4 Gy | ||
| Mukherjee S,[52] 2013, SCALOP | (12 weeks Gem-Cape) Gem –RT vs. Cape –RT | 38 Gem-RT 36 Cape-RT |
50.4Gy | Median OS significantly better with Cape-RT |